bioRxivMicrobiology
High-throughput sequencing-based neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1 influenza strains
A. N. Loes, R. A. L. Tarabi, J. Huddleston, L. Touyon, S. S. Wong, S. M. Cheng, N. H. Leung, W. W. Hannon, T. Bedford, S. Cobey, B. J. Cowling, J. D. Bloom
Abstract
The high genetic diversity of influenza viruses means that traditional serological assays have too low throughput to measure serum antibody neutralization titers against all relevant strains. To overcome this challenge, we have developed a sequencing-based neutralization assay that simultaneously measures titers against many viral strains using small serum volumes via a workflow similar to traditional neutralization assays. The key innovation is to incorporate unique nucleotide barcodes into the hemagglutinin (HA) genomic segment, and then pool viruses with numerous different barcoded HA variants and quantify infectivity of all of them simultaneously using next-generation sequencing. With this approach, a single researcher performed the equivalent of 2,880 traditional neutralization assays (80 serum samples against 36 viral strains) in approximately one month. We applied the sequencing-based assay to quantify the impact of influenza vaccination on neutralization titers against recent human H1N1 strains for individuals who had or had not also received a vaccine in the previous year. We found that the viral strain specificities of the neutralizing antibodies elicited by vaccination vary among individuals, and that vaccination induced a smaller increase in titers for individuals who had also received a vaccine the previous year--although the titers six months after vaccination were similar in individuals with and without the previous-year vaccination. We also identified a subset of individuals with low titers to a subclade of recent H1N1 even after vaccination. This study demonstrates the utility of high-throughput sequencing-based neutralization assays that enable titers to be simultaneously measured against many different viral strains. We provide a detailed experimental protocol (DOI: https://dx.doi.org/10.17504/protocols.io.kqdg3xdmpg25/v1) and a computational pipeline (https://github.com/jbloomlab/seqneut-pipeline) for the sequencing-based neutralization assays to facilitate the use of this method by others.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Near real-time data on the human neutralizing antibody landscape to influenza virus as of early 2026 to inform vaccine-strain selection
Caroline Kikawa, John Huddleston, … Jesse D. Bloom·Virus EvolutionPeer-reviewed·Jan 1, 2026
- Near real-time data on the human neutralizing antibody landscape to influenza virus to inform vaccine-strain selection in September 2025
Caroline Kikawa, John Huddleston, … Jesse D. Bloom·Virus EvolutionPeer-reviewed·Jan 1, 2025
- High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains
Caroline Kikawa, Andrea N. Loes, … Jesse D. Bloom·eLifePeer-reviewed·Feb 23, 2026
- Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants
Caroline Kikawa, Andrew Butler, … Jesse D. Bloom·bioRxiv·Sep 21, 2026
- A rapid and flexible microneutralization assay for serological assessment of influenza viruses
K. E. Rumfelt, W. J. Fitzsimmons, … A. S. Lauring·bioRxiv·Feb 2, 2023
- Low levels of H5N1 HA and NA antibodies in the human population are boosted by seasonal A/H1N1 infection but not by A/H3N2 infection or influenza vaccination
Anne P. Werner, Cosette G. Schneider, … Andrew S Pekosz·mBioPeer-reviewed·Oct 31, 2025